Lung cancer represents the world’s leading cause of cancer deaths. Sex differences in the incidence and mortality rates for various types of lung cancers have been identified, but the biological and endocrine mechanisms implicated in these disparities have not yet been determined. While some cancers such as lung adenocarcinoma are more commonly found among women than men, others like squamous cell carcinoma display the opposite pattern or show no sex differences. Associations of tobacco product use rates, susceptibility to carcinogens, occupational exposures, and indoor and outdoor air pollution have also been linked to differential rates of lung cancer occurrence and mortality between sexes. While roles for sex hormones in other types of cancers affecting women or men have been identified and described, little is known about the influence of sex hormones in lung cancer. One potential mechanism identified to date is the synergism between estrogen and some tobacco compounds, and oncogene mutations, in inducing the expression of metabolic enzymes, leading to enhanced formation of reactive oxygen species and DNA adducts, and subsequent lung carcinogenesis. In this review, we present the literature available regarding sex differences in cancer rates, associations of male and female sex hormones with lung cancer, the influence of exogenous hormone therapy in women, and potential mechanisms mediated by male and female sex hormone receptors in lung carcinogenesis. The influence of biological sex on lung disease has recently been established, thus new research incorporating this variable will shed light on the mechanisms behind the observed disparities in lung cancer rates, and potentially lead to the development of new therapeutics to treat this devastating disease.
SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalABrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. Epub ahead of print 4 February 2021. DOI: 10.3322/caac.21660.
2.
SiegelRLMillerKDFuchsHEJemalA.Cancer statistics, 2021. CA A Cancer J Clin2021;
71:7–33
3.
MalhotraJMalvezziMNegriELa VecchiaCBoffettaP.Risk factors for lung cancer worldwide. Eur Respir J2016;
48:889–902
4.
SametJMAvila-TangEBoffettaPHannanLMOlivo-MarstonSThunMJRudinCM.Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res2009;
15:5626–45
5.
AlbergAJBrockMVFordJGSametJMSpivackSD.Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2013;
143:e1S–e29S
6.
KurtOKZhangJPinkertonKE.Pulmonary health effects of air pollution. Curr Opin Pulm Med2016;
22:138–43
7.
PopeCABurnettRTThunMJCalleEEKrewskiDItoKThurstonGD.Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA2002;
287:1132–41
8.
KreuzerMGerkenMHeinrichJKreienbrockLWichmannHE.Hormonal factors and risk of lung cancer among women?Int J Epidemiol2003;
32:263–71
9.
HydeZFlickerLMcCaulKAAlmeidaOPHankeyGJChubbSAYeapBB.Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study. Cancer Epidemiol Biomarkers Prev2012;
21:1319–29
10.
Fidler-BenaoudiaMMTorreLABrayFFerlayJJemalA.Lung cancer incidence in young women vs. young men: a systematic analysis in 40 countries. Int J Cancer2020;
147:811–9
11.
MattiuzziCLippiG.Current cancer epidemiology. J Epidemiol Glob Health2019;
9:217–22
12.
RiveraMP.Lung cancer in women: differences in epidemiology, biology, histology, and treatment outcomes. Semin Respir Crit Care Med2013;
34:792–801
13.
StapelfeldCDammannCMaserE.Sex-specificity in lung cancer risk. Int J Cancer2020;
146:2376–82
14.
JhaP.Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer2009;
9:655–64
15.
Lortet-TieulentJRenteriaESharpLWeiderpassEComberHBaasPBrayFCoeberghJWSoerjomataramI.Convergence of decreasing male and increasing female incidence rates in major tobacco-related cancers in Europe in 1988-2010. Eur J Cancer2015;
51:1144–63
16.
BartaJAPowellCAWisniveskyJP.Global epidemiology of lung cancer. Ann Glob Health2019;
85:1–16
17.
TurnerMCAndersenZJBaccarelliADiver Wr Gapstur Sm PopeCAPradaDSametJThurstonGCohenA. Outdoor air pollution and cancer: an overview of the current evidence and public health recommendations. CA Cancer J Clin. Epub ahead of print 25 August 2020. DOI: 103322/caac.21632.
18.
KristAHDavidsonKWMangioneCMBarryMJCabanaMCaugheyABDavisEMDonahueKEDoubeniCAKubikMLandefeldCSLiLOgedegbeGOwensDKPbertLSilversteinMStevermerJTsengCWWongJBForceUPST.Screening for lung cancer: US Preventive Services Task Force Recommendation Statement. JAMA2021;
325:962–70
19.
OzlüTBülbülY.Smoking and lung cancer. Tuberk Toraks2005;
53:200–9
20.
RiveraGAWakeleeH.Lung cancer in never smokers. Adv Exp Med Biol2016;
893:43–57
21.
Barrera-RodriguezRMorales-FuentesJ.Lung cancer in women. Lung Cancer (Auckl)2012;
3:79–89
22.
Ben-Zaken CohenSParéPDManSFSinDD.The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism. Am J Respir Crit Care Med2007;
176:113–20
23.
PengJMeirelesSIXuXSmithWESlifkerMJRielSLZhaiSZhangGMaXKurzerMSMaGXClapperML.Estrogen metabolism in the human lung: impact of tumorigenesis, smoke, sex and race/ethnicity. Oncotarget2017;
8:106778–89
24.
DickinsonMEFlennikenAMJiXTeboulLWongMDWhiteJKMeehanTFWeningerWJWesterbergHAdissuHBakerCNBowerLBrownJMCaddleLBChianiFClaryDCleakJDalyMJDenegreJMDoeBDolanMEEdie Helmut FuchsSMGailus-DurnerVGalliAGambadoroAGallegosJGuoSHornerNRHsuCWJohnsonSJKalagaSKeithLCLanoueLLawsonTNLekMMarkMMarschallSMasonJMcElweeMLNutter Snlm PetersonKARamirez-SolisRRowlandDJRyderESamochaKESeavittJRSelloumMSzoke-KovacsZTamuraMTrainorAGTudoseIWakanaSWarrenJWendlingOWestDBWongLYoshikiAWurstWMacArthurDGTocchini-ValentiniGPGaoXFlicekPBradleyASkarnesWCJusticeMJParkinsonHEMooreMWellsSBraunRESvensonKLde AngelisMHHeraultYMohunTMallonAMHenkelmanRMBrownSDMAdamsDJLloydKCKMcKerlieCBeaudetAL.Murray MbsaConsortium.Corrigendum: high-throughput discovery of novel developmental phenotypes. Nature2017;
551:398.
25.
PortJLYamaguchiKDuBDeLMChangMHeerdtPMKopelovichLMarcusCBAltorkiNKSubbaramaiahKDannenbergAJ.Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis2004;
25:2275–81
26.
MollerupSBergeGBaeraRSkaugVHewerAPhillipsDHStangelandLHaugenA.Sex differences in risk of lung cancer: expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. Int J Cancer2006;
119:741–4
27.
KureEHRybergDHewerAPhillipsDHSkaugVBaeraRHaugenA.p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis1996;
17:2201–5
28.
BartaJAMcMahonSB.Lung-enriched mutations in the p53 tumor suppressor: a paradigm for tissue-specific gain of oncogenic function. Mol Cancer Res2019;
17:3–9
29.
YangPWangYWampflerJAXieDStoddardSMSheJMidthunDE.Trends in subpopulations at high risk for lung cancer. J Thorac Oncol2016;
11:194–202
30.
JemalAThunMJRiesLAHoweHLWeirHKCenterMMWardEWuXCEhemanCAndersonRAjaniUAKohlerBEdwardsBK.Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst2008;
100:1672–94
31.
EscobedoLGPeddicordJP.Smoking prevalence in US birth cohorts: the influence of gender and education. Am J Public Health1996;
86:231–6
32.
SiegfriedJM.Women and lung cancer: does oestrogen play a role?Lancet Oncol2001;
2:506–13
33.
JamalAPhillipsEGentzkeASHomaDMBabbSDKingBANeffLJ.Current cigarette smoking among adults - United States, 2016. MMWR Morb Mortal Wkly Rep2018;
67:53–9
34.
TownsendEAMillerVMPrakashYS.Sex differences and sex steroids in lung health and disease. Endocr Rev2012;
33:1–47
35.
WakeleeHAWangWSchillerJHLangerCJSandlerABBelaniCPJohnsonDHGroupECO.Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol2006;
1:441–6
36.
ChenKYHsiaoCFChangGCTsaiYHSuWCPerngRPHuangMSHsiungCAChenCJYangPCGroupGS.Hormone replacement therapy and lung cancer risk in Chinese. Cancer2007;
110:1768–75
37.
HouLWangDBaccarelliA.Environmental chemicals and microRNAs. Mutat Res2011;
714:105–12
38.
ImkampKBernalVGrzegorzcykMHorvatovichPVermeulenCJHeijinkIHGuryevVKerstjensHAMvan den BergeMFaizA.Gene network approach reveals co-expression patterns in nasal and bronchial epithelium. Sci Rep2019;
9:15835
39.
ZhangXSebastianiPLiuGSchembriFDumasYMLangerEMAlekseyevYO'ConnorGTBrooksDRLenburgMESpiraA.Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. Physiol Genomics2010;
41:1–8
40.
SiegfriedJMStabileLP.Estrongenic steroid hormones in lung cancer. Semin Oncol2014;
41:5–16
41.
SiegfriedJM.Early changes in pulmonary gene expression following tobacco exposure shed light on the role of estrogen metabolism in lung carcinogenesis. Cancer Prev Res (Phila) ) 2010;
3:692–5
42.
CadranelJMauguenAFallerMZalcmanGBuisineMPWesteelVLongchamptEWislezMCoudertBDanielCChetailleBMichielsSBlonsHSolassolJDe FraipontFFoucherPUrbanTLacroixLPoulotVQuoixEAntoineMDantonGMorinFChouaidCPignonJP.Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project–part 2). J Thorac Oncol2012;
7:1490–502
43.
LeiLWangWXYuZYLiangXBPanWWChenHFWangLPFangYWangMXuCWFangMY.A real-world study in advanced non-small cell lung cancer with KRAS mutations. Transl Oncol2020;
13:329–35
44.
Beau-FallerMTexierMBlonsHRichardNEscandeFMelaabiSLizardSDe FraipontFLongchamptEMorinFZalcmanGPignonJPCadranelJ.Clinical relevance of EGFR- or KRAS-mutated subclones in patients with advanced non-small-cell lung cancer receiving erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2). Clin Lung Cancer2019;
20:222–30
45.
DuboisCRocksNBlacherSPrimacIGallezAGarcía-CaballeroMGérardCBrouchetLNoëlALenfantFCataldoDPequeuxC.Lymph/angiogenesis contributes to sex differences in lung cancer through oestrogen receptor alpha signalling. Endocr Relat Cancer2019;
26:201–16
46.
SherTDyGKAdjeiAA.Small cell lung cancer. Mayo Clin Proc2008;
83:355–67
47.
SusterDIMino-KenudsonM.Molecular pathology of primary non-small cell lung cancer. Arch Med Res2020;
51:784–98
48.
KiyoharaCOhnoY.Sex differences in lung cancer susceptibility: a review. Gend Med2010;
7:381–401
49.
NorthCMChristianiDC.Women and lung cancer: what is new?Semin Thorac Cardiovasc Surg2013;
25:87–94
50.
SchveigertDKrasauskasADidziapetrieneJKalibatieneDCicenasS.Smoking, hormonal factors and molecular markers in female lung cancer. Neoplasma2016;
63:504–9
51.
MezaRMeernikCJeonJCoteML.Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One2015;
10:e0121323
52.
ZangEAWynderEL.Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst1996;
88:183–92
53.
KabirZConnollyGNClancyL.Sex-differences in lung cancer cell-types? An epidemiologic study in Ireland. Ulster Med J2008;
77:31–5
54.
EttingerDSWoodDEAisnerDLAkerleyWBaumanJChirieacLRD'AmicoTADeCampMMDillingTJDobelbowerMDoebeleRCGovindanRGubensMAHennonMHornLKomakiRLacknerRPLanutiMLealTALeischLJLilenbaumRLinJLooBWMartinsROttersonGAReckampKRielyGJSchildSEShapiroTAStevensonJSwansonSJTauerKYangSCGregoryKHughesM.Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw2017;
15:504–35
55.
LindemanNICaglePTAisnerDLArcilaMEBeasleyMBBernickerEHColasaccoCDacicSHirschFRKerrKKwiatkowskiDJLadanyiMNowakJAShollLTemple-SmolkinRSolomonBSouterLHThunnissenETsaoMSVenturaCBWynesMWYatabeY.Updated Molecular Testing Guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn2018;
20:129–59
56.
ChanprapaphKVachiramonVRattanakaemakornP.Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract2014;
2014:734249–57
57.
LandiLCappuzzoF.Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. Expert Rev Clin Pharmacol2016;
9:203–14
58.
CamidgeDRKimHRAhnMJYangJCHHanJYHochmairMJLeeKHDelmonteAGarcía CampeloMRKimDWGriesingerFFelipECalifanoRSpiraAGettingerSNTiseoMLinHMGuptaNHanleyMJNiQZhangPPopatS.Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol2020;
38:3592–603
59.
TomasiniPEgeaJSouquet-BressandMGreillierLBarlesiF.Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases. Ther Adv Respir Dis2019;
13:1753466619831906
60.
SgambatoACasaluceFMaionePGridelliC.Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther2018;
18:71–80
61.
RoskoskiR.ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacol Res2017;
121:202–12
62.
ManningGWhyteDBMartinezRHunterTSudarsanamS.The protein kinase complement of the human genome. Science2002;
298:1912–34
63.
RittmeyerABarlesiFWaterkampDParkKCiardielloFvon PawelJGadgeelSMHidaTKowalskiDMDolsMCCortinovisDLLeachJPolikoffJBarriosCKabbinavarFFronteraOADe MarinisFTurnaHLeeJSBallingerMKowanetzMHePChenDSSandlerAGandaraDRGroupOS.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet2017;
389:255–65
64.
MazieresJRittmeyerAGadgeelSHidaTGandaraDRCortinovisDLBarlesiFYuWMathenyCBallingerMParkK.Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. J Thorac Oncol2021;
16:140–50
65.
SocinskiMAJotteRMCappuzzoFOrlandiFStroyakovskiyDNogamiNRodríguez-AbreuDMoro-SibilotDThomasCABarlesiFFinleyGKelschCLeeAColemanSDengYShenYKowanetzMLopez-ChavezASandlerAReckMGroupIS.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med2018;
378:2288–301
66.
ConfortiFPalaLBagnardiVVialeGDe PasTPaganEPennacchioliECocorocchioEFerrucciPFDe MarinisFGelberRDGoldhirschA.Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J Natl Cancer Inst2019;
111:772–81
67.
XiaoDPanHLiFWuKZhangXHeJ.Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma. Oncotarget2016;
7:22857–64
68.
WangSCowleyLALiuXS.Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy. Molecules2019;
24:3214–26
69.
BaikCSEatonKD.Estrogen signaling in lung cancer: an opportunity for novel therapy. Cancers (Basel)2012;
4:969–88
70.
SchillerJHHarringtonDBelaniCPLangerCSandlerAKrookJZhuJJohnsonDHGroupECO.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med2002;
346:92–8
71.
WaqarSNMorgenszternD.Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther2017;
180:16–23
72.
TarhiniAKotsakisAGoodingWShuaiYPetroDFriedlandDBelaniCPDacicSArgirisA.Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res2010;
16:5900–7
73.
SunJMKimJRDoIGLeeSYLeeJChoiYLAhnJSAhnMJParkK.A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. Br J Cancer2013;
109:1482–7
74.
BotticelliAOnestiCEZizzariICerbelliBSciattellaPOcchipintiMRobertoMDi PietroFBonifacinoAGhidiniMViciPPizzutiLNapoletanoCStrigariLD'AmatiGMazzucaFNutiMMarchettiP.The sexist behaviour of immune checkpoint inhibitors in cancer therapy. Oncotarget2017;
8:99336–46
75.
PatelJD.Lung cancer in women. J Clin Oncol2005;
23:3212–8
76.
PaggiMGVonaRAbbruzzeseCMalorniW.Gender-related disparities in non-small cell lung cancer. Cancer Lett2010;
298:1–8
77.
Harichand-HerdtSRamalingamSS.Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. Semin Oncol2009;
36:572–80
78.
RosellRKarachaliouNArrietaO.Novel molecular targets for the treatment of lung cancer. Curr Opin Oncol2020;
32:37–43
79.
GriffinRRamirezRA.Molecular targets in non-small cell lung cancer. Ochsner J2017;
17:388–92
80.
TestaUCastelliGPelosiE.Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers (Basel)2018;
10:248–329
81.
CrespoPLeónJ.Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci2000;
57:1613–36
82.
RaviRKWeberEMcMahonMWilliamsJRBaylinSMalAHarterMLDillehayLEClaudioPPGiordanoANelkinBDMabryM.Activated raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest1998;
101:153–9
83.
SamuelsMLWeberMJBishopJMMcMahonM.Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Mol Cell Biol1993;
13:6241–52
84.
JännePAMannHGhiorghiuD.Study design and rationale for a randomized, placebo-controlled, double-blind study to assess the efficacy and safety of selumetinib in combination with docetaxel as second-line treatment in patients with KRAS-mutant advanced non-small cell lung cancer (SELECT-1). Clin Lung Cancer2016;
17:e1–e4
85.
MeloskyBBradburyPTuDFlorescuMReimanANicholasGBasappaNRothensteinJGoffinJRLaurieSAWheatley-PricePLeighlNGossGReaumeMNButtsCMurrayNCardCKoJBlaisNGraySLuiHBrown-WalkerPKaurahPPrenticeLMSeymourL.Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: a randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. Lung Cancer2019;
133:48–55
86.
JancíkSDrábekJRadziochDHajdúchM.Clinical relevance of KRAS in human cancers. J Biomed Biotechnol2010;
2010:150960
87.
KodazHTaştekinEErdoğanBHacıbekiroğluİTozkırHGürkanHTürkmenEDemirkanBUzunoğluSÇiçinİ.KRAS mutation in small cell lung carcinoma and extrapulmonary small cell cancer. Balkan Med J2016;
33:407–10
88.
BaumlJMickRZhangYWattCDVachaniAAggarwalCEvansTLangerC.Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?Lung Cancer2013;
81:347–53
89.
StabileLPDacicSLandSRLenznerDEDhirRAcquafondataMLandreneauRJGrandisJRSiegfriedJM.Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res2011;
17:154–64
90.
Rodriguez-LaraVPeña-MirabalEBaez-SaldañaREsparza-SilvaALGarcía-ZepedaECerbon CervantesMADiazDFortoulTI.Estrogen receptor beta and CXCR4/CXCL12 expression: differences by sex and hormonal status in lung adenocarcinoma. Arch Med Res2014;
45:158–69
91.
Rodriguez-LaraVHernandez-MartinezJMArrietaO.Influence of estrogen in non-small cell lung cancer and its clinical implications. J Thorac Dis2018;
10:482–97
92.
RosellRMoranTQueraltCPortaRCardenalFCampsCMajemMLopez-VivancoGIslaDProvencioMInsaAMassutiBGonzalez-LarribaJLPaz-AresLBoverIGarcia-CampeloRMorenoMACatotSRolfoCReguartNPalmeroRSánchezJMBastusRMayoCBertran-AlamilloJMolinaMASanchezJJTaronM, Spanning Lung Cancer Group.
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med2009;
361:958–67
93.
PietrasRJMárquezDCChenHWTsaiEWeinbergOFishbeinM.Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids2005;
70:372–81
94.
LevinER.Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol2003;
17:309–17
95.
StabileLPLykerJSGubishCTZhangWGrandisJRSiegfriedJM.Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res2005;
65:1459–70
96.
GiovanniniMBelliCVillaEGregorcV.Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?J Thorac Oncol2008;
3:684–5
97.
MollerupSJørgensenKBergeGHaugenA.Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer2002;
37:153–9
98.
KawaiHIshiiAWashiyaKKonnoTKonHYamayaCOnoIOgawaJ.Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. Anticancer Res2005;
25:4693–8
99.
JännePAYangJCKimDWPlanchardDOheYRamalingamSSAhnMJKimSWSuWCHornLHaggstromDFelipEKimJHFrewerPCantariniMBrownKHDickinsonPAGhiorghiuSRansonM.AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med2015;
372:1689–99
100.
YuHAArcilaMERekhtmanNSimaCSZakowskiMFPaoWKrisMGMillerVALadanyiMRielyGJ.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res2013;
19:2240–7
101.
KadotaKEguchiTVillena-VargasJWooKMSimaCSJonesDRTravisWDAdusumilliPS.Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration. Oncotarget2015;
6:27505–18
102.
OlakJColsonY.Gender differences in lung cancer: have we really come a long way, baby?J Thorac Cardiovasc Surg2004;
128:346–51
103.
ChuSCHsiehCJWangTFHongMKChuTY.Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: a population-based study. Cancer Epidemiol2017;
48:22–8
104.
BrücklWMAl-BatranSEFickerJHWirtzRMAtmacaA. [
Estrogen receptors and their impact for prognosis and therapy of lung cancer - new insights to an underestimated mechanism. Pneumologie2015;
69:350–60].
105.
HsuLHLiuKJTsaiMFWuCRFengACChuNMKaoSH.Estrogen adversely affects the prognosis of patients with lung adenocarcinoma. Cancer Sci2015;
106:51–9
106.
StabileLPDavisALGubishCTHopkinsTMLuketichJDChristieNFinkelsteinSSiegfriedJM.Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res2002;
62:2141–50
107.
HsuLHChuNMKaoSH.Estrogen, estrogen receptor and lung cancer. Int J Mol Sci2017;
18:1713–29
108.
SmidaTBrunoTCStabileLP.Influence of estrogen on the NSCLC microenvironment: a comprehensive picture and clinical implications. Front Oncol2020;
10:137
109.
SchabathMBWuXVassilopoulou-SellinRVaporciyanAASpitzMR.Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res2004;
10:113–23
110.
SchwartzAGWenzlaffASPrysakGMMurphyVCoteMLBrooksSCSkafarDFLonardoF.Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol2007;
25:5785–92
111.
DouMZhuKFanZZhangYChenXZhouXDingXLiLGuZGuoMYanMDengXShenPWangS.Reproductive hormones and their receptors may affect lung cancer. Cell Physiol Biochem2017;
44:1425–34
112.
MusialCZauchaRKuban-JankowskaAKoniecznaLBelkaMMarino GammazzaABaczekTCappelloFWozniakMGorska-PonikowskaM.Plausible role of estrogens in pathogenesis, progression and therapy of lung cancer. Int J Environ Res Public Health2021;
18:648–63
113.
MeirelesSIEstevesGHHirataRPeriSDevarajanKSlifkerMMosierSLPengJVadhanamMVHurstHENevesEJReisLFGairolaCGGuptaRCClapperML.Early changes in gene expression induced by tobacco smoke: evidence for the importance of estrogen within lung tissue. Cancer Prev Res (Phila)2010;
3:707–17
114.
SiegfriedJM.Smoking out reproductive hormone actions in lung cancer. Mol Cancer Res2014;
12:24–31
115.
FuentesNSilveyraP.Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol2019;
116:135–70
116.
FuentesNSilveyraP.Endocrine regulation of lung disease and inflammation. Exp Biol Med (Maywood)2018;
243:1313–22
117.
HuangQZhangZLiaoYLiuCFanSWeiXAiBXiongJ.17β-estradiol upregulates IL6 expression through the ERβ pathway to promote lung adenocarcinoma progression. J Exp Clin Cancer Res2018;
37:133–51
118.
SkovBGFischerBMPappotH.Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer2008;
59:88–94
119.
Márquez-GarbánDCChenHWGoodglickLFishbeinMCPietrasRJ.Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci2009;
1155:194–205
120.
BurnsTFStabileLP.Targeting the estrogen pathway for the treatment and prevention of lung cancer. Lung Cancer Manag2014;
3:43–52
121.
ZhangGYanamalaNLathropKLZhangLKlein-SeetharamanJSrinivasH.Ligand-independent antiapoptotic function of estrogen receptor-beta in lung cancer cells. Mol Endocrinol2010;
24:1737–47
122.
LiangJXieQLiPZhongXChenY.Mitochondrial estrogen β receptor inhibits cell apoptosis via interaction with bad in a ligand-independent manner. Mol Cell Biochem2015;
401:71–86
123.
LiaoTLTzengCRYuCLWangYPKaoSH.Estrogen receptor-β in mitochondria: implications for mitochondrial bioenergetics and tumorigenesis. Ann N Y Acad Sci2015;
1350:52–60
124.
DaumSHagenHNaismithEWolfDPircherA.The role of anti-angiogenesis in the treatment landscape of non-small cell lung cancer - new combinational approaches and strategies of neovessel inhibition. Front Cell Dev Biol2020;
8:610903
125.
SiegfriedJMGubishCTRothsteinMEHenryCStabileLP.Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol2012;
7:485–95
126.
LiuCLiaoYFanSFuXXiongJZhouSZouMWangJ.G-protein-coupled estrogen receptor antagonist G15 decreases estrogen-induced development of non-small cell lung cancer. Oncol Res2019;
27:283–92
127.
SathishVMartinYNPrakashYS.Sex steroid signaling: implications for lung diseases. Pharmacol Ther2015;
150:94–108
128.
Marquez-GarbanDCMahVAlaviMMareshELChenHWBagryanovaLHorvathSChiaDGaronEGoodglickLPietrasRJ.Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids2011;
76:910–20
129.
KazmiNMárquez-GarbánDCAivazyanLHamiltonNGaronEBGoodglickLPietrasRJ.The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. Lung Cancer Manag2012;
1:259–72
130.
SkjefstadKRichardsenEDonnemTAndersenSKiselevYGrindstadTHaldSMAl-ShibliKBremnesRMBusundLTAl-SaadST.Prognostic role of progesterone receptor expression in non-small cell lung cancer patients: gender-related impacts and correlation with disease-specific survival. Steroids2015;
98:29–36
131.
IshibashiHSuzukiTSuzukiSNiikawaHLuLMikiYMoriyaTHayashiSHandaMKondoTSasanoH.Progesterone receptor in non-small cell lung cancer–a potent prognostic factor and possible target for endocrine therapy. Cancer Res2005;
65:6450–8
132.
WilsonCMMcPhaulMJ.A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol1996;
120:51–7
133.
MikkonenLPihlajamaaPSahuBZhangFPJänneOA.Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol2010;
317:14–24
134.
ChangCLeeSOYehSChangTM.Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene2014;
33:3225–34
135.
LanzinoMSisciDMorelliCGarofaloCCatalanoSCasaburiICapparelliCGiordanoCGiordanoFMaggioliniMAndòS.Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells–identification of a novel androgen response element. Nucleic Acids Res2010;
38:5351–65
136.
YehS-DYP-CLuH-HChangCWuC-W.Targeting androgen receptor as a new potential therapeutic approach to battle tobacco carcinogens-induced non-small cell lung cancer. J Transl Med2012;
10:1–2
137.
Becerra-DiazMSongMHellerN.Androgen and androgen receptors as regulators of monocyte and macrophage biology in the healthy and diseased lung. Front Immunol2020;
11:1698
138.
Becerra-DíazMStricklandABKeselmanAHellerNM.Androgen and androgen receptor as enhancers of M2 macrophage polarization in allergic lung inflammation. J Immunol2018;
201:2923–33
139.
ZhouJWangHSunQLiuXWuZWangXFangWMaZ.miR-224-5p-enriched exosomes promote tumorigenesis by directly targeting androgen receptor in non-small cell lung cancer. Mol Ther Nucleic Acids2021;
23:1217–28
140.
RodriguezCSpencer FeigelsonHDekaAPatelAVJacobsEJThunMJCalleEE.Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev2008;
17:655–60
141.
ChlebowskiRTSchwartzAGWakeleeHAndersonGLStefanickMLMansonJERodaboughRJChienJWWactawski-WendeJGassMKotchenJMJohnsonKCO'SullivanMJOckeneJKChenCHubbellFAInvestigatorsWHI.Oestrogen plus progestin and lung cancer in postmenopausal women (women's health initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet2009;
374:1243–51
142.
ChlebowskiRTWakeleeHPettingerMRohanTLiuJSimonMTindleHMessinaCJohnsonKSchwartzAGassMWactawski-WendeJ.Estrogen plus progestin and lung cancer: follow-up of the Women's Health Initiative Randomized Trial. Clin Lung Cancer2016;
17:10–7.e1
143.
TaioliEWynderEL.Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst1994;
86:869–70
144.
LiuYInoueMSobueTTsuganeS.Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer2005;
117:662–6
145.
RamnathNMenezesRJLoewenGDuaPEidFAlkhaddoJPaganelliGNatarajanNReidME.Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. Oncology2007;
73:305–10
146.
SiegfriedJMHershbergerPAStabileLP.Estrogen receptor signaling in lung cancer. Semin Oncol2009;
36:524–31
147.
BaikCSStraussGMSpeizerFEFeskanichD.Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev2010;
19:2525–33
148.
KatcoffHWenzlaffASSchwartzAG.Survival in women with NSCLC: the role of reproductive history and hormone use. J Thorac Oncol2014;
9:355–61
149.
ClagueJReynoldsPHendersonKDSullivan-HalleyJMaHLaceyJVChangSDelclosGLDuXLFormanMRBernsteinL.Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California Teachers Study. PLoS One2014;
9:e103735
150.
BrintonLASchwartzLSpitzMRParkYHollenbeckARGierachGL.Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Causes Control2012;
23:487–96
151.
Abdel-RahmanO.Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis. Int J Clin Oncol2020;
25:885–91
152.
GantiAKSahmounAEPanwalkarAWTendulkarKKPottiA.Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol2006;
24:59–63
153.
JinCLangB.Hormone replacement therapy and lung cancer risk in women: a meta-analysis of cohort studies: hormone replacement therapy and lung cancer risk. Medicine (Baltimore)2019;
98:e17532
154.
TitanALHeHLuiNLiouDBerryMShragerJBBackhusLM.The influence of hormone replacement therapy on lung cancer incidence and mortality. J Thorac Cardiovasc Surg2020;
159:1546–56.e4
155.
JeonKHShinDWHanKKimDYooJEJeongSMChoJH.Female reproductive factors and the risk of lung cancer in postmenopausal women: a nationwide cohort study. Br J Cancer2020;
122:1417–24
